AI Portfolio Summary
In 2025 Q4, Saturn V Capital Management LP maintained a portfolio of 25 distinct positions. The most significant new addition to the portfolio was ALUMIS INC, which now represents 5.62% of the total fund value. They heavily accumulated shares in VAXCYTE INC, increasing their position by 1.3%. Conversely, Saturn V Capital Management LP completely exited their position in NEWAMSTERDAM PHARMA .
Total Positions
25
Quarter
2025 Q4
Top Holding
ABVX (16.1%)
Top 10 Concentration
76.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-25 of 25
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ABVX
ABIVAX SA
|
Healthcare | 16.07% | 14.92% |
#1
Prev: #1
|
6.5 | -152,045 | -19.0% |
P
S
|
649,179 | $87,545,034 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 9.97% | 13.72% |
#2
Prev: #2
|
6.0 | -108,391 | -2.4% |
P
S
|
4,496,487 | $54,317,563 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 7.93% | 6.38% |
#3
2
Prev: #5
|
4.2 | -807,977 | -39.9% |
P
S
|
1,217,064 | $43,230,113 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JAZZ
JAZZ PHARMACEUT...
|
Healthcare | 7.74% | 8.69% |
#4
1
Prev: #3
|
4.1 | -52,540 | -17.5% |
P
S
|
248,070 | $42,171,900 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 6.77% | 6.23% |
#5
1
Prev: #6
|
3.7 | 10,499 | 1.3% |
P
S
|
798,940 | $36,863,092 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 6.42% | 7.42% |
#6
2
Prev: #4
|
2.6 | -885,853 | -33.1% |
P
S
|
1,788,616 | $34,985,329 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 5.81% | 4.85% |
#7
3
Prev: #10
|
4.8 | 253,701 | 28.6% |
P
S
|
1,140,033 | $31,635,916 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CELC
CELCUITY INC
|
Healthcare | 5.80% | 5.13% |
#8
1
Prev: #7
|
2.3 | -156,733 | -33.1% |
P
S
|
317,095 | $31,627,055 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALMS
ALUMIS INC
|
Healthcare | 5.62% | — |
#9
Prev: #—
|
5.7 | 3,135,953 | no change |
NEW
|
3,135,953 | $30,606,901 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 4.35% | 4.94% |
#10
1
Prev: #9
|
2.2 | -42,468 | -12.5% |
P
S
|
298,429 | $23,698,247 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 4.26% | — |
#11
Prev: #—
|
5.2 | 5,800,530 | no change |
NEW
|
5,800,530 | $23,202,120 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNPR
MONOPAR THERAPE...
|
Healthcare | 3.90% | 2.78% |
#12
4
Prev: #16
|
4.6 | 170,331 | 109.6% |
P
S
|
325,701 | $21,268,275 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IVVD
INVIVYD INC
|
Healthcare | 3.51% | — |
#13
Prev: #—
|
4.9 | 7,735,386 | no change |
NEW
|
7,735,386 | $19,106,403 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 3.35% | 2.95% |
#14
1
Prev: #15
|
3.8 | 353,194 | 30.7% |
P
S
|
1,504,880 | $18,269,243 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMMX
IMMIX BIOPHARMA...
|
Healthcare | 2.88% | — |
#15
Prev: #—
|
4.7 | 2,999,169 | no change |
NEW
|
2,999,169 | $15,685,654 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCS
OCULIS HOLDING ...
|
Healthcare | 1.89% | — |
#16
Prev: #—
|
4.3 | 516,761 | no change |
NEW
|
516,761 | $10,319,717 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 1.45% | — |
#17
Prev: #—
|
4.1 | 3,856,799 | no change |
NEW
|
3,856,799 | $7,906,438 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 1.30% | 3.91% |
#18
6
Prev: #12
|
0.5 | -451,847 | -61.5% |
P
S
|
282,692 | $7,070,127 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OVID
OVID THERAPEUTI...
|
Healthcare | 0.75% | — |
#19
Prev: #—
|
3.8 | 2,500,000 | no change |
NEW
|
2,500,000 | $4,075,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IVA
INVENTIVA SA
|
Healthcare | 0.24% | — |
#20
Prev: #—
|
3.6 | 283,166 | no change |
NEW
|
283,166 | $1,316,722 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NAMS
NEWAMSTERDAM PH...
|
Healthcare | 0.00% | 0.96% |
Sold All 😨
(Was: #17) |
0.0 | -153,147 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LENZ
LENZ THERAPEUTI...
|
Healthcare | 0.00% | 3.76% |
Sold All 😨
(Was: #14) |
0.0 | -368,176 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRUS
MERUS N V
|
Healthcare | 0.00% | 3.80% |
Sold All 😨
(Was: #13) |
0.0 | -184,135 | -100.0% |
CLOSED
|
— | $— | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 0.00% | 4.44% |
Sold All 😨
(Was: #11) |
0.0 | -503,701 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 0.00% | 5.12% |
Sold All 😨
(Was: #8) |
0.0 | -579,895 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 25 holdings